Ken Griffin Adamis Pharmaceuticals Corp Call Options Transaction History

Citadel Advisors LLC

  • $509 Billion
  • Q1 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.1 - $0.3 $2,140 - $6,420
-21,400 Reduced 58.95%
14,900 $1,000
Q4 2022

Feb 14, 2023
SELL
$0.14 - $0.22 $1,134 - $1,782
-8,100 Reduced 18.24%
36,300 $6,000
Q3 2022

Nov 14, 2022
SELL
$0.24 - $0.54 $4,416 - $9,936
-18,400 Reduced 29.3%
44,400 $9,000

About Adamis Pharmaceuticals Corp

ADMP Quotes by TradingView
  • Ticker ADMP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 149,983,008
  • Market Cap $73.5M
  • Description
  • Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emerg...
More about ADMP
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email